Almaghrabi, Ruba
Alyahyawi, Yara
Keane, Peter https://orcid.org/0000-0001-8738-9693
Mian, Syed A. https://orcid.org/0000-0001-8005-2860
Habel, Khadidja https://orcid.org/0009-0007-6471-1468
Atkinson, Amelia
Ward, Carl https://orcid.org/0000-0003-0889-9025
Bayley, Rachel
Sargas, Claudia
Menendez, Pablo
Murphy, George J. https://orcid.org/0000-0003-3464-793X
Sobahy, Turki
Baghdadi, Mohammed A.
Flemban, Arwa F. https://orcid.org/0000-0001-8761-4280
Kabrah, Saeed M. https://orcid.org/0000-0003-2992-8497
Torres-Ruiz, Raul
Papapetrou, Eirini P. https://orcid.org/0000-0001-7002-417X
Akerman, Ildem https://orcid.org/0000-0002-9875-1421
Raghavan, Manoj https://orcid.org/0000-0002-5464-2602
Barragan, Eva https://orcid.org/0000-0001-6735-0038
Bonnet, Dominique https://orcid.org/0000-0002-4735-5226
Bonifer, Constanze https://orcid.org/0000-0002-4267-0825
Garcia, Paloma https://orcid.org/0000-0001-5582-8575
Article History
Received: 2 August 2023
Accepted: 16 May 2025
First Online: 1 July 2025
Competing interests
: Pablo Menendez is co-founder of OneChain Immunotherapeutics, a spin-off company from the Josep Carreras Leukaemia Institute. The remaining authors declare no competing interests.